Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H72O16 |
| Molecular Weight | 869.0436 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 26 / 26 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]6O[C@H](CO)[C@@H](O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)O[C@]19CC[C@@H](C)CO9
InChI
InChIKey=VNONINPVFQTJOC-ZGXDEBHDSA-N
InChI=1S/C45H72O16/c1-19-9-14-45(54-18-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(52)34(50)32(48)22(4)56-41)37(53)38(29(17-46)58-42)59-40-35(51)33(49)31(47)21(3)55-40/h7,19-22,24-42,46-53H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1
| Molecular Formula | C45H72O16 |
| Molecular Weight | 869.0436 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 26 / 26 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28677156Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25993784 | https://www.ncbi.nlm.nih.gov/pubmed/28796245 | https://www.ncbi.nlm.nih.gov/pubmed/28849197 | https://www.ncbi.nlm.nih.gov/pubmed/28435431
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28677156
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25993784 | https://www.ncbi.nlm.nih.gov/pubmed/28796245 | https://www.ncbi.nlm.nih.gov/pubmed/28849197 | https://www.ncbi.nlm.nih.gov/pubmed/28435431
Dioscin is a natural steroid saponin derived from several plants, showing the potent anti-cancer effect against a variety of tumor cell lines. Pharmacological studies have shown that dioscin processes anti-cerebral ischemia/reperfusion injury, anti-liver fibrosis and anti-obesity effects. Dioscin markedly inhibited cell viability, colony formation, motility and induced apoptosis in prostate cancer cells. Dioscin remarkably suppressed the migratory and invasive capacities of melanoma cells. In preclinical models, dioscin showed significant anti-metastatic effects and suppress the tumor cell malignancy.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28689917 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways. | 2014-12-01 |
|
| Dioscin enhances methotrexate absorption by down-regulating MDR1 in vitro and in vivo. | 2014-06-01 |
|
| Protective effects of dioscin against alcohol-induced liver injury. | 2014-03 |
|
| Dioscin, a natural steroid saponin, shows remarkable protective effect against acetaminophen-induced liver damage in vitro and in vivo. | 2012-10-02 |
|
| Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. | 2005 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28796245
Mice 80 mg/kg/day for 21 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28796245
The PC3 cells were seeded in 96-well plates (5000 cells/well) in DMEM/F12 medium and incubated overnight, and the PC3 cell-derived mammospheres were seeded in growth medium for 5 days culturing. Subsequently, various concentrations of dioscin (0.18–92 μM for PC3 monolayers; 0.36–184 μM for mammospheres) were added in each well. After PC3 cells were incubated for 24 h, the cell viability was analyzed using the MTT assay kit
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:30:54 GMT 2025
by
admin
on
Mon Mar 31 23:30:54 GMT 2025
|
| Record UNII |
3B95U4OLWV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3B95U4OLWV
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
SUB33941
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
119245
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
m4590
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID50903916
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
19057-60-4
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
100000127804
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY | |||
|
74023
Created by
admin on Mon Mar 31 23:30:54 GMT 2025 , Edited by admin on Mon Mar 31 23:30:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |